Bladder Cancer

Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy - Beyond the Abstract

The introduction of immunotherapy strategies in the therapeutic armamentarium for almost all types of tumors could redesign the role of fluorodeoxyglucose positron emission tomography (FDG-PET/CT). Immune stimulation related to immunotherapy can lead to inflammatory reactions in many organs and the differential diagnosis between immune-related changes and progression of disease needs caution. Some data suggest that the development of immune-related adverse events (irAEs) could be associated with improved clinical outcomes in patients treated with immunotherapy, and this hypothesis has also been proposed by considering irAEs detected on PET/CT in advanced solid tumors.1,2 However, the role of Fluorodeoxyglucose Positron Emission Tomography (PET/CT) in the context of non-metastatic, localized solid tumors receiving immune-checkpoint inhibitors is still an under-investigated field.

European Commission Approves Avelumab for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma

San Francisco, CA (UroToday.com) -- EMD Serono, the Healthcare business sector of Merck KGaA, Darmstadt, Germany in the US and Canada, and Pfizer Inc. announced that the European Commission (EC) has approved BAVENCIO® (avelumab) as monotherapy for the first-line maintenance treatment of adult patients with locally advanced or metastatic urothelial carcinoma (UC) who are progression-free following platinum-based chemotherapy.

The role of palliative radiotherapy in the management of elderly and frail patients with advanced bladder cancer: A survey by the AIRO uro-group.

Radiotherapy (RT) is rarely used in the palliative management of muscle-invasive bladder cancer (MIBC). This survey aims to explore current care patterns within the Italian Radiation Oncologist community on this topic.

The long noncoding RNA KTN1-AS1 promotes bladder cancer tumorigenesis via KTN1 cis-activation and the consequent initiation of Rho GTPase-mediated signaling.

Accumulating evidence supports the hypothesis that long noncoding RNAs (lncRNAs) are involved in several physiological and pathological conditions, including cancer. Here, we investigated the potential role of lncRNAs in bladder cancer.

Bladder tumor subtype commitment occurs in carcinoma in-situ driven by key signaling pathways including ECM remodeling.

Basal and luminal subtypes of invasive bladder tumors have significant prognostic and predictive impacts for patients. However, it remains unclear whether tumor subtype commitment occurs in non-invasive urothelial lesions or in carcinoma in situ (CIS) and which gene pathways are important for bladder tumor progression.

[18F]Fluoro-Deoxy-Glucose Positron Emission Tomography to Evaluate Lymph Node Involvement in Patients with Muscle-Invasive Bladder Cancer Receiving Neoadjuvant Pembrolizumab - Beyond the Abstract

Improving clinical staging remains an unmet clinical need in muscle-invasive bladder cancer (MIBC). Contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI) - the standard radiological techniques to stage MIBC - are affected by accuracy limitations leading to clinical to pathologic stage discrepancy in a not negligible number of cases. The role of [18F]Fluoro-deoxy-glucose positron emission tomography/computed tomography (FDG-PET/CT) to evaluate pre-operative lymph node involvement (LNI) in MIBC is still under debate and a recent study reported limited utility in patients with clinically negative lymph nodes (cN0).1

Can Anesthetics Affect Bladder Cancer Recurrence? Total Intravenous Versus Volatile Anesthesia in Patients Undergoing Robot-Assisted Radical Cystectomy: A Single Institution Retrospective Analysis - Beyond the Abstract

Bladder cancer is one of the most commonly diagnosed malignancies of the genitourinary system with an expected 81,400 new cases and 17,980 deaths in the United States for 2020.1 While radical cystectomy with bilateral pelvic lymphadenectomy remains the gold standard treatment for surgically eligible patients with either non-metastatic muscle-invasive disease (MIBC)2 or persistent high-grade non-MIBC,3 at the time of surgical resection there might be an increase in shedding of cancer cells into the circulation.4 Recent reports have found that roughly 32% of patients after five years from surgery experience recurrence.5 In addition to surgery itself, several other surgical factors, one of which being anesthetic technique may suppress anti-tumor immunity allowing circulating cancer cells to survive and enhance migration and invasion at a target site.4

Administration of neoadjuvant chemotherapy for muscle-invasive bladder cancer in real life: Are urologists still too cautious?

Neoadjuvant chemotherapy (NAC) is now recommended to treat muscle-invasive bladder cancer (MIBC) but is not always executed in real life. This study aims to evaluate the proportion of patients with MIBC who receive an optimal NAC, and to present the predictive factors of its achievement.

Identifying Distinct High Unmet-Need Phenotypes and Their Associated Bladder Cancer Patient Demographic, Clinical, Psychosocial, and Functional Characteristics: Results of Two Clustering Methods.

We explored phenotypes of high unmet need of patients with bladder cancer and their associated patient demographic, clinical, psychosocial, and functional characteristics.

Patients (N=159) were recruited from the Bladder Cancer Advocacy Network and completed an online survey measuring unmet needs (BCNAS-32), quality of life (FACT-Bl), anxiety and depression (HADS), coping (BRIEF Cope), social support (SPS), and self-efficacy beliefs (GSE).

SLC35F2, a Transporter Sporadically Mutated in the Untranslated Region, Promotes Growth, Migration, and Invasion of Bladder Cancer Cells.

Bladder cancer is a very heterogeneous disease and the molecular mechanisms of carcinogenesis and progression are insufficiently investigated. From the DNA sequencing analysis of matched non-muscle-invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC) samples from eight patients, we identified the tumour-associated gene SLC35F2 to be mutated in the 5' and 3' untranslated region (UTR).